← Back to Search

Dopamine Agonist

Cabergoline 1 MG for Inhibition of Lactation (LISTA Trial)

Phase 2

Waitlist Available

Led By Andrea Henkel, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 4 after procedure

Awards & highlights

LISTA Trial Summary

This trialstudies a drug to reduce breast engorgement pain after second-trimester abortion or stillbirth. It aims to provide a treatment option for those who don't wish to parent.

LISTA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 4 after procedure

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 4 after procedure

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 4 after procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants Reporting Breast Pain

Secondary outcome measures

Number of Participants Experiencing Side-effects

Number of Participants Reporting Significant Bother From Breast Pain

Number of Participants Reporting Significant Bother From Side-effects

+1 more

LISTA Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: CabergolineExperimental Treatment1 Intervention

After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.

Group II: PlaceboPlacebo Group1 Intervention

After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cabergoline 1 MG

2021

Completed Phase 2

~80

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,393 Previous Clinical Trials

17,341,163 Total Patients Enrolled

Andrea Henkel, MDPrincipal Investigator - Stanford University

Stanford University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this type of clinical study been conducted before?

"Research on Cabergoline 1 MG began in 2013 with a trial sponsored by RECORDATI GROUP. The Phase 4 drug approval was granted after the 413-person study concluded, leading to 6 active studies involving 41 cities and 30 countries."

Answered by AI

How many participants are being accepted for this experiment?

"At this moment, the study is not accepting new patients. Initially posted on February 18th 2021, and last updated October 22nd 2022, recruitment has been suspended. Fortunately there are other trials recruiting volunteers; two with inhibition of physiological lactation therapy and six for Cabergoline 1 MG."

Answered by AI

Are there any opportunities to participate in this research endeavor?

"As per the clinicaltrials.gov website, this trial is not currently recruiting patients; it was initially posted on February 18th 2021 and last modified October 22nd 2022. Luckily, there are other 8 studies actively looking for participants at present."

Answered by AI

Have any other investigations been conducted on the impact of Cabergoline 1 MG?

"Currently, there are 6 active trials researching the effects of Cabergoline 1 MG with one in Phase 3. 97 medical sites across the world have begun their own trial for this drug and a majority of these locations are located in Boston, Massachusetts."

Answered by AI

What afflictions is Cabergoline 1 MG typically employed to alleviate?

"Cabergoline 1 MG is commonly prescribed for the suppression of lactation, as well as pituitary adenoma, idiopathic hyperprolactinemic disorder and some forms of therapeutic antilactation."

Answered by AI

Has the Food and Drug Administration authorized Cabergoline 1 MG for public use?

"The safety of Cabergoline 1 MG was judged as a 2 since this is a Phase 2 trial, so there exists some evidence of its security but no proof yet concerning effectiveness."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss

Andrea Henkel, MD 2021. "Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04701333.